Philip D. Hall - Concepedia

Author

Philip D. Hall

Medical University of South Carolina

Also Known As

P D Hall, P Hall, P. D. Hall, Philip D Hall, Philip D. Hall, Philip Hall

Publications

901

Citations

H-Index

Concepts

All Affiliations

Medical University of South Carolina Wake Forest University National Institutes of Health National Cancer Institute MUSC Hollings Cancer Center

About

Philip D. Hall is an author at Medical University of South Carolina specializing in medicine, immunology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	311
2	Health Sciences	3	3	99
3	Natural Sciences	1	1	47
4	Allergy	1	1	29
5	Anesthesia	1	1	11

Philip D. Hall

Publications

828

Citations

H-Index

Page 1

	Year	Citations
Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Arthur E. Frankel, Bayard L. Powell, Philip D. Hall, PubMed	2002	113
Single‐Dose Rasburicase 6 mg in the Management of Tumor Lysis Syndrome in Adults Anne McDonnell, Kristi L Lenz, Debra Frei‐Lahr, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy	2006	83
Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE John B. Bossaer, Philip D. Hall, Elizabeth Garrett‐Mayer Supportive Care in Cancer Health SciencesAntimicrobial StewardshipAntibioticsHealthcare-associated InfectionVancomycin-resistant Enterococci	2010	60
Interstitial Diphtheria Toxin-Epidermal Growth Factor Fusion Protein Therapy Produces Regressions of Subcutaneous Human Glioblastoma Multiforme Tumors in Athymic Nude Mice Tie Fu Liu, Philip D. Hall, Kimberley A. Cohen, Clinical Cancer Research	2005	57
Modulation of the Apoptotic Response of Human Myeloid Leukemia Cells to a Diphtheria Toxin Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein Arthur E. Frankel, Philip D. Hall, Chris Burbage, Blood	1997	51
Antibody Response to DT–GM, a Novel Fusion Toxin Consisting of a Truncated Diphtheria Toxin (DT) Linked to Human Granulocyte–Macrophage Colony Stimulating Factor (GM), during a Phase I Trial of Patients with Relapsed or Refractory Acute Myeloid Leukemia Philip D. Hall, Gabriel Virella, Tony E. Willoughby, Clinical Immunology Hematological MalignancyImmunoengineeringImmune RegulationImmunologyHematology	2001	49
Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials Jeffrey O Urieto, TieFu Liu, J Black, Protein Expression and Purification Microbial ToxinToxinologyNatural SciencesImmunologyClinical Trials	2003	47
Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein. Donna E. Hogge, Cheryl L. Willman, Robert J. Kreitman, PubMed	1998	44
The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Philip D. Hall, H Benko, Kathryn Hogan, PubMed	1995	40
Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Arthur E. Frankel, Michelle M. Lilly, Robert J. Kreitman, PubMed	1998	36

Page 1